You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TOPIC 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER
SBC: DIAGNOLOGIX, LLC Topic: NCIChemotherapy may control but rarely cure metastatic cancers. Remarkably, modern immunotherapies, including cell-based therapies, have cured metastatic melanomas and other types of cancers. A major challenge for all cell therapies in general is the need to develop cost-effective and efficient manufacturing and delivery capabilities. We have recently established an innovative cell isolation technolo ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 377: Bridging the Guideline Implementation Gap: Clinical Decision Support to Improve Cancer Symptom Management
SBC: Cognitive Medical Systems, Inc. Topic: NCIAdvances in clinical research have yielded many evidence-based guidelines to help clinicians provide the right care for the right patient at the right time; however, studies suggest that nearly half the time, that care does not reach the patient. Clinical decision support (CDS) is an information technology-enabled method to identify missed opportunities and optimize care. This proposal seeks to sy ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 371: Validation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
SBC: Riptide Bioscience, Inc. Topic: NCIRadiotherapy, a key anticancer therapy, acts not only by killing cancer cells, but also by activating the body's immune system to attack the remaining cancer cells. However, the immune-stimulating effect is weakened by the tumor's capacity to reprogram immune cells, particularly macrophages, so that they instead actively promote tumor growth. RP-185 (Riptide Biosciences, Vallejo, CA),an engineered ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 376: A noninvasive PET imaging strategy for longitudinal monitoring of immune contexture in the tumor microenvironmen
SBC: CELLSIGHT TECHNOLOGIES, INC. Topic: NCIImmunotherapy has transformed cancer treatment, but therapy response ranges between 5% to 60% depending on tumor and treatment type. Accumulating evidence points to number and type of immune cell infiltrates within tumors as the culprit for failure. To enable higher success rates, novel treatments aim to prime tumors for immunotherapy by improving the immune milieu within the tumor microenvironmen ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 375: 18F PET Tracer For Imaging PD-L1 (Moonshot)
SBC: SIBTECH, INC. Topic: NCINew therapies, designed to enhance anti-tumor immunity are based on the blockade of the checkpoint components, either PD-1 on immune cells or PD-L1 on tumor cells. This strategy, while being spectacularly successful in some patients for some cancers, fails for many other patients. The expression of PD-L1 is highly dynamic and its prevalence within tumors can vary significantly over time. The curre ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 374: Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention
SBC: TheraNano LLC Topic: NCIHere we propose to study two injectable formulations that provide different delivery routes for Talazoparib, potent PAPR inhibitor: An implant, InCeT-Talazoparib, which can be injected directly in the tumor where it will act as a sustained release depot of Talazoparib over a prolonged period of approximately 30 days. It delivers 100% of the drug to the tumor site with almost no systemic toxicity. ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 363- CONNECTING CANCER CAREGIVERS TO CARE TEAMS: DIGITAL PLATFORMS TO SUPPORT INFORMAL CANCER CAREGIVING
SBC: Medable Inc. Topic: NCITOGETHER is a mobile application on a smart software system that informal caregivers will use to develop and implement home-based care for cancer survivors. It will help alleviate the cancer caregiving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan. The goal of this Fast-Track project is to develop and validate a final TOGETHER ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 373: alteRNAting-seq
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: NCIDuring this Phase I SBIR project, Electronic BioSicences (EBS) will develop a direct, long-read, RNA strand sequencing methodology that is capable of sequencing both canonical and specific modified nucleotides with high-accuracy. This will result in the development of technology wherein a single-stranded RNA (ssRNA) molecule is translocated through a nanopore reader using an applied voltage bias a ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 372: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics
SBC: AVANTGEN INC Topic: NCIThere is an increasing appreciation that dogs with naturally occurring cancers may be a better model system for evaluating cancer therapeutics than the traditional mouse model systems. However, use of dogs for evaluating the emerging class of immunotherapeutics for oncology is limited by the availability of suitable reagents to mentor the response of the canine immune system. The majority of reage ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topic 372: Development of the Fully Humanized 9-in-9-out Rat Drug Metabolism-CYP450 Model, Using the Active Genetic: Gene Drive Technology
SBC: SYNBAL INC Topic: NCIIn this Fast track SBIR grant we aim, by the end of Phase II, to prepare and commercialize a fully humanized rat with Knock-out of many rat drug metabolism related CYP450's (9-in-9-out Rat Drug Metabolism-CYP450 Model) and Knock-in of the human counterpart. IN PHASE I we will develop an Active Genes: Gene Drive (AG:GD) rat - a rat with a properly configured Cas9 to power Active Genetics (AG); AND, ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health